scholarly journals Measurement properties of the Headache Impact Test (HIT‐6™ Brazil) in primary and secondary headaches

2021 ◽  
Author(s):  
Juliana Pradela ◽  
Débora Bevilaqua‐Grossi ◽  
Thais C. Chaves ◽  
Fabiola Dach ◽  
Gabriela F. Carvalho
Keyword(s):  
Impact Test ◽  
Measurement Properties ◽  
Secondary Headaches ◽  
Headache Impact

scholarly journals Case report: Manual therapies promote resolution of persistent post-concussion symptoms in a 24-year-old athlete

2021 ◽  
Vol 9 ◽  
pp. 2050313X2095222
Author(s):  
Susan Vaughan Kratz
Keyword(s):  
Case Report ◽  
Symptom Severity ◽  
Impact Test ◽  
Manual Therapies ◽  
Symptom Checklist ◽  
Post Concussion Syndrome ◽  
Persistent Symptoms ◽  
Short Period ◽  
History Of ◽  
Headache Impact

This case report illustrates the treatment outcomes of a collegiate athlete presenting with an 18-month history of post-concussion syndrome who received a series of mixed manual therapies in isolation of other therapy. Persistent symptoms were self-reported as debilitating, contributing to self-removal from participation in school, work, and leisure activities. Patient and parent interviews captured the history of multiple concussions and other sports-related injuries. Neurological screening and activities of daily living were baseline measured. Post-Concussion Symptom Checklist and Headache Impact Test-6™ were utilized to track symptom severity. Treatments applied included craniosacral therapy, manual lymphatic drainage, and glymphatic techniques. Eleven treatment sessions were administered over 3 months. Results indicated restoration of oxygen saturation, normalized pupil reactivity, and satisfactory sleep. Post-concussion syndrome symptom severity was reduced by 87% as reflected by accumulative Post-Concussion Symptom Checklist scores. Relief from chronic headaches was achieved, reflected by Headache Impact Test-6 scores. Restoration of mood and quality of life were reported. A 6-month follow-up revealed symptoms remained abated with full re-engagement of daily activities. The author hypothesized that post-concussion syndrome symptoms were related to compression of craniosacral system structures and lymphatic fluid stagnation that contributed to head pressure pain, severe sleep deprivation, and multiple neurological and psychological symptoms. Positive outcomes over a relatively short period of time without adverse effects suggest these therapies may offer viable options for the treatment of post-concussion syndrome.

scholarly journals Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study

2021 ◽  
pp. jnnp-2020-324396
Author(s):  
Michel Lanteri-Minet ◽  
Peter J Goadsby ◽  
Uwe Reuter ◽  
Shihua Wen ◽  
Peggy Hours-Zesiger ◽  
...  
Keyword(s):  
Functional Outcomes ◽  
Impact Test ◽  
Work Productivity ◽  
Placebo Treatment ◽  
Episodic Migraine ◽  
Activity Impairment ◽  
Everyday Activities ◽  
Point Reduction ◽  
Patient Reported ◽  
Headache Impact

ObjectiveTo evaluate the effect of erenumab on patient-reported, functional outcomes in patients with episodic migraine (EM) in whom 2–4 preventives were not useful from the Phase 3b LIBERTY study.MethodsAs previously reported, 246 patients with EM with 2–4 prior failed preventives were randomised 1:1 to subcutaneous erenumab 140 mg or placebo every 4 weeks for 12 weeks. This analysis evaluated Migraine Physical Function Impact Diary (MPFID), Headache Impact Test (HIT-6) and Work Productivity and Activity Impairment (WPAI) scores at Week 12. P values were nominal without multiplicity adjustment.ResultsErenumab significantly improved MPFID-Physical Impairment (PI) and Everyday Activities (EA) scores versus placebo (treatment difference (TD) (95% CI) MPFID-PI: −3.5 (−5.7 to –1.2) (p=0.003); MPFID-EA: −3.9 (−6.1 to –1.7)) (p<0.001) at 12 weeks. Patients on erenumab were more likely to have a ≥5-point reduction in MPFID score (OR vs placebo (95% CI) MPFID-EA: 2.1 (1.2 to 3.6); MPFID-PI: 2.5 (1.4 to 4.5)). A similar trend was observed for HIT-6 (TD: −3.0; p<0.001); significantly higher proportions of patients on erenumab reported a ≥5-point reduction (OR (95% CI): 2.4 (1.4 to 4.1)). In three out of four WPAI domains, erenumab showed improvement versus placebo.ConclusionAt 12 weeks, erenumab was efficacious on functional outcomes in patients with EM in whom 2–4 preventives were not useful.Trial registration detailsClinicalTrials.gov identifier: NCT03096834.

Reference Values for the Headache Impact Test-6 Questionnaire

2021 ◽  
Author(s):  
Megan N. Houston ◽  
Haley A. Bookbinder ◽  
Sean P. Roach ◽  
Jeremy D. Ross ◽  
Michael J. Aderman ◽  
...  
Keyword(s):  
Reference Values ◽  
Impact Test ◽  
Headache Impact

scholarly journals A Case Report on a Patient Treated with Combined Korean Medicine for Chronic Headache with Digestive Symptoms

2021 ◽  
Vol 42 (5) ◽  
pp. 923-90
Author(s):  
Gyu-cheol Choi ◽  
Ji-eun Bae ◽  
Jae-won Park ◽  
Dong-jin Kim ◽  
Jeong-su Hong
Keyword(s):  
Medical Treatment ◽  
Chronic Headache ◽  
Impact Test ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Five Dimensions ◽  
End Of Treatment ◽  
Numerical Rating ◽  
Headache Impact

Objectives: The purpose of this study was to examine the effect of combined Korean medical treatment on chronic headache with digestive symptoms.Methods: We collected data from October to December 2020 and evaluated the efficacy of combined Korean medical treatment using the Korean Headache Impact Test-g (KHIT-6), European Quality of Life Five Dimensions (EQ5D) Scale, and Numerical Rating Scale (NRS) at admission, after two weeks of hospitalization, and on discharge.Results: At the end of treatment, the patient had increased EQ5D and reduced KHIT-6 and NRS scores.Conclusions: After the combined Korean medical treatment, the patient showed improvement, suggesting the efficacy of treatment.

scholarly journals Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT‐6) Total and Item‐Specific Scores in Chronic Migraine

2020 ◽  
Vol 60 (9) ◽  
pp. 2003-2013
Author(s):  
Carrie R. Houts ◽  
R. J. Wirth ◽  
James S. McGinley ◽  
Roger Cady ◽  
Richard B. Lipton
Keyword(s):  
Chronic Migraine ◽  
Impact Test ◽  
Meaningful Change ◽  
Headache Impact

A Comparative Analysis of Amytripiline, Flunnarazine and Topiramate in the treatment of Primary Headache

2021 ◽  
Vol 18 (2) ◽  
pp. 45-48
Author(s):  
Babu Ram Pokharel ◽  
Gopal Raman Sharma ◽  
Prabhaw Upadhyaya ◽  
Samip Jung Budhathoki ◽  
Santosh Thapa ◽  
...  
Keyword(s):  
Impact Test ◽  
Primary Headache ◽  
Headache Disorder ◽  
Categorical Variables ◽  
Primary Headaches ◽  
Chi Square ◽  
Headache Patient ◽  
Primary Headache Disorder ◽  
Chi Square Test ◽  
Headache Impact

Introduction Primary headache disorder, characterized by recurrent headache is the most prevalent disease leading to widespread ill health and impaired quality of life. In Nepal headache is one of the most common cause of patient attending neurology clinic. Amitriptyline, Flunarizine and Topiramate are common drugs in the treatment of primary headache. We conducted this study to compare the efficacy of drugs namely Amitriptyline, Flunarizine and Topiramate in the treatment of primary headache Materials and Methods This is the retrospective data analysis of primary headache patient treated with amitriptyline, flunarizine and topiramate. On their first, second and third subsequent visits, Headache Impact Test 6 Scoring was done by a medical person. Patient were treated clinically. After third follow up data were analyzed using SPSS version 20.0. Categorical variables were compared by chi-square test, paired sample t-test, ANOVA test and Welch test. Results A total of 142 patient data was analyzed. The most common age group were between 20 to 39 years (56.34%) followed by 40 to 59 years (33.80%). Female were predominant in the group 124 (87.32%).  All three medication Amitriptyline, Flunarizine and Topiramate were able to significantly lower Headache impact test  -17.23 ± 6.643, -14.06 ± 7.155, -15.82 ± 5.907 respectively (P- <0.001). Amitriptyline was found to be better than other two drugs in reducing Headache Impact Test. Conclusion All three drugs namely Amitriptyline, Flunarizine and Topiramate, are significantly effective in the treatment of primary headache. Though tension type of headache is the most common type of headache, amitriptyline seems to be equally effective in treatment with other primary headaches.

Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab

Cephalalgia ◽  
2018 ◽  
Vol 38 (10) ◽  
pp. 1622-1631 ◽  
Author(s):  
Dawn C Buse ◽  
Richard B Lipton ◽  
Yngve Hallström ◽  
Uwe Reuter ◽  
Stewart J Tepper ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Impact Test ◽  
Episodic Migraine ◽  
Health Related Quality ◽  
Double Blind ◽  
Related Quality ◽  
Health Related ◽  
Headache Impact ◽  
Assessment Questionnaire

Background We evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine. Methods Patients enrolled in a phase 3, 6-month, double-blind, placebo-controlled study of once-monthly erenumab 70 and 140 mg for migraine prevention (STRIVE) used an eDiary during the baseline and double-blind treatment phases to complete validated, specific questionnaires, including the modified (monthly) Migraine Disability Assessment Questionnaire; Headache Impact Test; and Migraine-Specific Quality of Life Questionnaire-role function-restrictive (MSQ-RFR), -role function-preventive (MSQ-RFP), and -emotional function (MSQ-EF). Results A total of 955 patients were randomized to receive erenumab 70 mg (n = 317), erenumab 140 mg (n = 319), or placebo (n = 319). Erenumab versus placebo resulted in significantly greater improvements in all patient-reported outcomes; changes from baseline were numerically higher with 140 mg erenumab. Improvements occurred rapidly and were maintained over 6 months of treatment. Between-group differences from placebo over months 4–6 for the 70- and 140-mg dose groups were, respectively, −2.1 and −2.8 for modified (monthly) Migraine Disability Assessment Questionnaire, −2.1 and −2.3 for Headache Impact Test, 5.1 and 6.5 for MSQ-RFR, 4.2 and 5.4 for MSQ-RFP, and 5.2 and 6.7 for MSQ-EF ( p < 0.001 for all). Erenumab also significantly reduced the proportion of patients with severe and very severe migraine-related disability and increased the proportion of patients with clinically meaningful improvements in migraine-related impact and health-related quality of life. Conclusion Erenumab reduced migraine disability and impact and improved patients’ health-related quality of life, reinforcing its role as a promising new therapy for migraine prevention.

The Headache Impact Test?? and the Short Pain Inventory??

2003 ◽  
Vol 17 (1) ◽  
pp. 23-32 ◽  
Author(s):  
Shaun G. Kilminster ◽  
Andrew Dowson ◽  
Mike Bundy
Keyword(s):  
Impact Test ◽  
Headache Impact

scholarly journals Measuring health-related quality of life in chronic headache: A comparative evaluation of the Chronic Headache Quality of Life Questionnaire and Headache Impact Test (HIT-6)

Cephalalgia ◽  
2021 ◽  
pp. 033310242110060
Author(s):  
Kirstie L Haywood ◽  
Felix Achana ◽  
Vivien Nichols ◽  
Gemma Pearce ◽  
Barbara Box ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Headache ◽  
Impact Test ◽  
Life Questionnaire ◽  
Specific Patient ◽  
Quality Of Life Questionnaire ◽  
Patient Reported ◽  
Smallest Detectable Change ◽  
Headache Impact

Objective To compare the quality and acceptability of a new headache-specific patient-reported measure, the Chronic Headache Quality of Life Questionnaire (CHQLQ) with the six-item Headache Impact Test (HIT-6), in people meeting an epidemiological definition of chronic headaches. Methods Participants in the feasibility stage of the Chronic Headache Education and Self-management Study (CHESS) (n = 130) completed measures three times during a 12-week prospective cohort study. Data quality, measurement acceptability, reliability, validity, responsiveness to change, and score interpretation were determined. Semi-structured cognitive interviews explored measurement relevance, acceptability, clarity, and comprehensiveness. Results Both measures were well completed with few missing items. The CHQLQ’s inclusion of emotional wellbeing items increased its relevance to participant’s experience of chronic headache. End effects were present at item level only for both measures. Structural assessment supported the three and one-factor solutions of the CHQLQ and HIT-6, respectively. Both the CHQLQ (range 0.87 to 0.94) and HIT-6 (0.90) were internally consistent, with acceptable temporal stability over 2 weeks (CHQLQ range 0.74 to 0.80; HIT-6 0.86). Both measures responded to change in headache-specific health at 12 weeks (CHQLQ smallest detectable change (improvement) range 3 to 5; HIT-6 2.1). Conclusions While both measures are structurally valid, internally consistent, temporally stable, and responsive to change, the CHQLQ has greater relevance to the patient experience of chronic headache. Trial registration number: ISRCTN79708100. Registered 16th December 2015, http://www.isrctn.com/ISRCTN79708100

Sign in / Sign up

Export Citation Format

Share Document